Literature DB >> 16103084

B-cell receptor translocation to lipid rafts and associated signaling differ between prognostically important subgroups of chronic lymphocytic leukemia.

David J Allsup1, Aura S Kamiguti, Ke Lin, Paul D Sherrington, Zoltan Matrai, Joseph R Slupsky, John C Cawley, Mirko Zuzel.   

Abstract

Chronic lymphocytic leukemia (CLL) is a highly heterogeneous disease in which interaction of the malignant cells with antigen is thought to play a key role. Individual CLL-cell clones markedly differ in their ability to respond to B-cell receptor ligation, but the mechanism underlying the frequent hyporesponsiveness is incompletely understood. Our aim was to further clarify the extent and cause of the B-cell receptor signaling abnormality in CLL and to assign pathophysiologic relevance to the presence or absence of B-cell receptor responsiveness. We show that extracellular signal-regulated kinase-2 phosphorylation, intracellular Ca2+ increases, CD79a phosphorylation, and translocation of the B-cell receptor to lipid rafts in response to ligation with anti-immunoglobulin M (as a surrogate for antigen) are features of CLL cells with relatively unmutated VH genes (<5% deviation from germ line) and a poor prognosis. B-cell receptor stimulation in these cases also promoted cell survival. In clones with mutated VH genes (>5% deviation from germ line), surface immunoglobulin M ligation failed to induce receptor translocation to rafts or to prolong cell survival. This failure of receptor translocation observed in mutated CLL cells was associated with the constitutive exclusion of the B-cell receptor from rafts by a mechanism involving src-dependent interactions between the B-cell receptor and the actin cytoskeleton. We conclude that exposure to antigen promotes the survival of unmutated CLL clones, contributing to the poor prognosis of this group. In contrast, hyporesponsive mutated CLL clones may have developed into a stage where continuous exposure to antigen results in relative tolerance to antigenic stimulation mediated by the exclusion of the B-cell receptor from lipid rafts.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16103084     DOI: 10.1158/0008-5472.CAN-03-1563

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  23 in total

Review 1.  ZAP-70: an essential kinase in T-cell signaling.

Authors:  Haopeng Wang; Theresa A Kadlecek; Byron B Au-Yeung; Hanna E Sjölin Goodfellow; Lih-Yun Hsu; Tanya S Freedman; Arthur Weiss
Journal:  Cold Spring Harb Perspect Biol       Date:  2010-05       Impact factor: 10.005

2.  ZAP-70 enhances IgM signaling independent of its kinase activity in chronic lymphocytic leukemia.

Authors:  Liguang Chen; Lang Huynh; John Apgar; Li Tang; Laura Rassenti; Arthur Weiss; Thomas J Kipps
Journal:  Blood       Date:  2007-11-29       Impact factor: 22.113

Review 3.  Molecular and cellular mechanisms of CLL: novel therapeutic approaches.

Authors:  Lisa Pleyer; Alexander Egle; Tanja Nicole Hartmann; Richard Greil
Journal:  Nat Rev Clin Oncol       Date:  2009-06-02       Impact factor: 66.675

4.  Excessive antigen reactivity may underlie the clinical aggressiveness of chronic lymphocytic leukemia stereotyped subset #8.

Authors:  Maria Gounari; Stavroula Ntoufa; Benedetta Apollonio; Nikos Papakonstantinou; Maurilio Ponzoni; Charles C Chu; Davide Rossi; Gianluca Gaidano; Nicholas Chiorazzi; Kostas Stamatopoulos; Paolo Ghia
Journal:  Blood       Date:  2015-04-21       Impact factor: 22.113

Review 5.  Targeting B-cell receptor signaling in leukemia and lymphoma: how and why?

Authors:  John C Allen; Fatima Talab; Joseph R Slupsky
Journal:  Int J Hematol Oncol       Date:  2016-05-26

Review 6.  Targeted therapy in chronic lymphocytic leukemia: past, present, and future.

Authors:  Alexey V Danilov
Journal:  Clin Ther       Date:  2013-09       Impact factor: 3.393

7.  Dipeptidyl peptidase 2 apoptosis assay determines the B-cell activation stage and predicts prognosis in chronic lymphocytic leukemia.

Authors:  Alexey V Danilov; Olga V Danilova; Jennifer R Brown; Arthur Rabinowitz; Andreas K Klein; Brigitte T Huber
Journal:  Exp Hematol       Date:  2010-09-24       Impact factor: 3.084

8.  Functional Differences between IgM and IgD Signaling in Chronic Lymphocytic Leukemia.

Authors:  Elisa Ten Hacken; Mariela Sivina; Ekaterina Kim; Susan O'Brien; William G Wierda; Alessandra Ferrajoli; Zeev Estrov; Michael J Keating; Thomas Oellerich; Cristina Scielzo; Paolo Ghia; Federico Caligaris-Cappio; Jan A Burger
Journal:  J Immunol       Date:  2016-08-17       Impact factor: 5.422

9.  Metadherin contribute to BCR signaling in chronic lymphocytic leukemia.

Authors:  Pei-Pei Li; Qing-Min Yao; Hui Zhou; Li-Li Feng; Xue-Ling Ge; Xiao Lv; Na Chen; Kang Lu; Xin Wang
Journal:  Int J Clin Exp Pathol       Date:  2014-03-15

10.  High TCL1 levels are a marker of B-cell receptor pathway responsiveness and adverse outcome in chronic lymphocytic leukemia.

Authors:  Marco Herling; Kaushali A Patel; Nicole Weit; Nils Lilienthal; Michael Hallek; Michael J Keating; Dan Jones
Journal:  Blood       Date:  2009-09-21       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.